Literature DB >> 18594199

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.

Gianluca Bossi1, Francesco Marampon, Revital Maor-Aloni, Bianca Zani, Varda Rotter, Moshe Oren, Sabrina Strano, Giovanni Blandino, Ada Sacchi.   

Abstract

Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness. Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded. To address this point, mimicking more physiological conditions, we now describe the establishment of a lentiviral-based system for conditional interference with mutant p53 expression. In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability. Moreover by using this system, microarray data were validated in vitro and in vivo and putative mutant p53 target genes that may contribute to its gain of function effects in cancer were identified. Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594199     DOI: 10.4161/cc.7.12.6161

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  48 in total

1.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

2.  Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies.

Authors:  Gabriella D'Orazi; Marco Cordani; Mara Cirone
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

Review 3.  The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Authors:  Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 4.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 5.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

6.  Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.

Authors:  Aymone Gurtner; Giuseppe Starace; Giuseppe Norelli; Giulia Piaggio; Ada Sacchi; Gianluca Bossi
Journal:  J Biol Chem       Date:  2010-03-11       Impact factor: 5.157

Review 7.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

8.  Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.

Authors:  F Garibaldi; E Falcone; D Trisciuoglio; T Colombo; K Lisek; D Walerych; G Del Sal; P Paci; G Bossi; G Piaggio; A Gurtner
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

Review 9.  Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.

Authors:  Bryant England; Tiangui Huang; Michael Karsy
Journal:  Tumour Biol       Date:  2013-06-05

10.  Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.

Authors:  Marie Brázdová; Timo Quante; Lars Tögel; Korden Walter; Christine Loscher; Vlastimil Tichý; Lenka Cincárová; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Nucleic Acids Res       Date:  2009-01-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.